Thioredoxin induces Tregs to generate an immunotolerant tumor microenvironment in metastatic melanoma

References

• Umansky V, Sevko A. Melanoma-induced immunosuppression and its neutralization. Semin Cancer Biol 2012; 22:319–26; PMID:22349515; http://dx.doi.org/10.1016/j.semcancer.2012.02.003
   PubMed Web of Science ®Google Scholar
• Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev 2012; 26:1131-55; PMID:22661227; http://dx.doi.org/10.1101/gad.191999.112
   PubMed Web of Science ®Google Scholar
• Zeiser R, Schnitzler M, Andrlova H, Hellige T, Meiss F. Immunotherapy for malignant melanoma. Curr Stem Cell Res Ther 2012; 7:217-28; PMID:22329580; http://dx.doi.org/10.2174/157488812799859883
   PubMed Web of Science ®Google Scholar
• Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012; 72:2162-71; PMID:22549946; http://dx.doi.org/10.1158/0008-5472.CAN-11-3687
   PubMed Web of Science ®Google Scholar
• Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy. Lancet Oncol 2012; 13:e32-42; PMID:22225723; http://dx.doi.org/10.1016/S1470-2045(11)70155-3
   PubMed Web of Science ®Google Scholar
• Policastro LL, Ibanez IL, Notcovich C, Duran HA, Podhajcer OL. The tumor microenvironment: characterization, redox considerations, and novel approaches for reactive oxygen species-targeted gene therapy. Antioxid Redox Signal 2013; 19:854-95; PMID:22794113; http://dx.doi.org/10.1089/ars.2011.4367
   PubMed Web of Science ®Google Scholar
• Lee S, Kim SM, Lee RT. Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance. Antioxid Redox Signal 2013; 18:1165-207; PMID:22607099; http://dx.doi.org/10.1089/ars.2011.4322
   PubMed Web of Science ®Google Scholar
• Powis G, Kirkpatrick DL. Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol 2007; 7:392-7; PMID:17611157; http://dx.doi.org/10.1016/j.coph.2007.04.003
   PubMed Web of Science ®Google Scholar
• Mahmood DF, Abderrazak A, El HK, Simmet T, Rouis M. The thioredoxin system as a therapeutic target in human health and disease. Antioxid Redox Signal 2013; 19:1266-303; PMID:23244617; http://dx.doi.org/10.1089/ars.2012.4757
   PubMed Web of Science ®Google Scholar
• Kakolyris S, Giatromanolaki A, Koukourakis M, Powis G, Souglakos J, Sivridis E, Georgoulias V, Gatter KC, Harris AL. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 2001; 7:3087-91; PMID:11595699
   PubMed Web of Science ®Google Scholar
• Raffel J, Bhattacharyya AK, Gallegos A, Cui H, Einspahr JG, Alberts DS, Powis G. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med 2003; 142:46-51; PMID:12878985; http://dx.doi.org/10.1016/S0022-2143(03)00068-4
   PubMed Web of Science ®Google Scholar
• Kim SJ, Miyoshi Y, Taguchi T, Tamaki Y, Nakamura H, Yodoi J, Kato K, Noguchi S. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin Cancer Res 2005; 11:8425-30; PMID:16322305; http://dx.doi.org/10.1158/1078-0432.CCR-05-0449
   PubMed Web of Science ®Google Scholar
• Csiki I, Yanagisawa K, Haruki N, Nadaf S, Morrow JD, Johnson DH, Carbone DP. Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer. Cancer Res 2006; 66:143-50; PMID:16397226; http://dx.doi.org/10.1158/0008-5472.CAN-05-1357
   PubMed Web of Science ®Google Scholar
• Lincoln DT, Ali EEM, Tonissen KF, Clarke FM. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res 2003; 23:2425-33; PMID:12894524
   PubMed Web of Science ®Google Scholar
• Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006; 24:1169-77; PMID:16505437; http://dx.doi.org/10.1200/JCO.2005.03.6830
   PubMed Web of Science ®Google Scholar
• Powell DJ, Jr, Felipe-Silva A, Merino MJ, Ahmadzadeh M, Allen T, Levy C, White DE, Mavroukakis S, Kreitman RJ, Rosenberg SA, et al. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. Journal of immunology (Baltimore, Md.: 1950) 2007; 179:4919-28; PMID:17878392; http://dx.doi.org/10.4049/jimmunol.179.7.4919
   PubMed Web of Science ®Google Scholar
• Quezada SA, Peggs KS, Simpson TR, Shen Y, Littman DR, Allison JP. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med 2008; 205:2125-38; PMID:18725522; http://dx.doi.org/10.1084/jem.20080099
   PubMed Web of Science ®Google Scholar
• Nicholaou T, Ebert LM, Davis ID, McArthur GA, Jackson H, Dimopoulos N, Tan B, Maraskovsky E, Miloradovic L, Hopkins W, et al. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res 2009; 15:2166-73; PMID:19276262; http://dx.doi.org/10.1158/1078-0432.CCR-08-2484
   PubMed Web of Science ®Google Scholar
• Bjoern J, Brimnes MK, Andersen MH, Thor SP, Svane IM. Changes in peripheral blood level of regulatory T cells in patients with malignant melanoma during treatment with dendritic cell vaccination and low-dose IL-2. Scand J Immunol 2011; 73:222-33; PMID:21204893; http://dx.doi.org/10.1111/j.1365-3083.2010.02494.x
   PubMed Web of Science ®Google Scholar
• Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, Akpinarli A, Fulton A, Tamada K, Strome SE, Antony PA. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. Journal of immunology (Baltimore, Md.: 1950) 2013; 190:4899-909; PMID:23536636; http://dx.doi.org/10.4049/jimmunol.1300271
   PubMed Web of Science ®Google Scholar
• Sim GC, Martin-Orozco N, Jin L, Yang Y, Wu S, Washington E, Sanders D, Lacey C, Wang Y, Vence L, et al. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest 2014; 124:99-110; PMID:24292706; http://dx.doi.org/10.1172/JCI46266
   PubMed Web of Science ®Google Scholar
• Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol 2011; 11:119-30; PMID:21267013; http://dx.doi.org/10.1038/nri2916
   PubMed Web of Science ®Google Scholar
• Burzyn D, Benoist C, Mathis D. Regulatory T cells in nonlymphoid tissues. Nat Immunol 2013; 14:1007-13; PMID:24048122; http://dx.doi.org/10.1038/ni.2683
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010; 127:759-67; PMID:20518016
   PubMed Web of Science ®Google Scholar
• Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011; 475:226-30; PMID:21753853; http://dx.doi.org/10.1038/nature10169
   PubMed Web of Science ®Google Scholar
• Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, Badoual C, Gey A, Ravel P, Marcheteau E, et al. A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood 2011; 118:4853-62; PMID:21908423; http://dx.doi.org/10.1182/blood-2011-01-329656
   PubMed Web of Science ®Google Scholar
• Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, Forbes B, Edelblute B, Collette B, Xing D, et al. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res 2011; 71:5522-34; PMID:21742774; http://dx.doi.org/10.1158/0008-5472.CAN-10-3143
   PubMed Web of Science ®Google Scholar
• Wan YY, Flavell RA. TGF-beta and regulatory T cell in immunity and autoimmunity. J Clin Immunol 2008; 28:647-59; PMID:18792765; http://dx.doi.org/10.1007/s10875-008-9251-y
   PubMed Web of Science ®Google Scholar
• Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P, Bergo MO. Antioxidants accelerate lung cancer progression in mice. Sci Transl Med 2014; 6:221ra15; PMID:24477002; http://dx.doi.org/10.1126/scitranslmed.3007653
   PubMed Web of Science ®Google Scholar
• Watson J. Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol 2013; 3:120144; PMID:23303309; http://dx.doi.org/10.1098/rsob.120144
   PubMed Web of Science ®Google Scholar
• Li W, Katoh H, Wang L, Yu X, Du Z, Yan X, Zheng P, Liu Y. FOXP3 regulates sensitivity of cancer cells to irradiation by transcriptional repression of BRCA1. Cancer Res 2013; 73:2170-80; PMID:23319807; http://dx.doi.org/10.1158/0008-5472.CAN-12-2481
   PubMed Web of Science ®Google Scholar
• Uy B, McGlashan SR, Shaikh SB. Measurement of reactive oxygen species in the culture media using Acridan Lumigen PS-3 assay. J Biomol Tech 2011; 22:95-107; PMID:21966257
   PubMedGoogle Scholar